Collaboration and License Agreement. The Collaboration and License Agreement shall be in full force and effect as of the date of the applicable Closing, and the Investor shall not have received notice of termination of the Collaboration and License Agreement on or prior to the date of the applicable Closing.
Collaboration and License Agreement. The MOU, or if later entered into the Collaboration and License Agreement, shall be in full force and effect.
Collaboration and License Agreement. The Company shall have duly executed and delivered the Collaboration and License Agreement;
Collaboration and License Agreement. The Investor shall have duly executed and delivered the Collaboration and License Agreement; and
Collaboration and License Agreement. The representations and warranties made by the Company in Article X of that certain Collaboration and License Agreement dated as of the date hereof (the “License Agreement”), are incorporated herein by this reference and made to Investor as though fully set forth herein.
Collaboration and License Agreement. This Collaboration and License Agreement dated the 22nd day of June, 2000 (the "Execution Date") is by and between Millennium Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware and having its principal office at 00 Xxxxxx Xxxxxx, Cambridge, Massachusetts 02139 ("Millennium"), and Aventis Pharmaceuticals Inc., a corporation organized and existing under the laws of the State of Delaware and having its principal office at Xxxxx 000-000, X.X. Xxx 0000, Xxxxxxxxxxx, Xxx Xxxxxx 00000 ("Aventis").
Collaboration and License Agreement. The Amended License Agreement shall be in full force and effect, and the Amendment No. 1 Effective Date (under and as defined therein) shall have occurred (or shall occur simultaneously with the Closing).
Collaboration and License Agreement. This COLLABORATION AND LICENSE AGREEMENT (this “Agreement”), effective as of July 16, 2007 (the “Effective Date”), is made by and between Edison Pharmaceuticals, Inc., a Delaware corporation, having a principal place of business at 5000 Xxxxxxx Xxxxx, Xxxxx 000, Xxx Xxxx, XX 00000 (“Edison”), and Penwest Pharmaceuticals Co., a Washington corporation, having a principal place of business at 30 Xxx Xxxxxxxxx Xxxx, Xxxxx 00, Xxxxxxx, XX 00000-0000 (“Penwest”).
Collaboration and License Agreement. This Collaboration and License Agreement (“Agreement”) is entered into as of this 1st day of November, 2003 (“Effective Date”), by and between Momenta Pharmaceuticals, Inc., a Delaware corporation (“Momenta”) with a principal place of business at 00 Xxxxxxx Xxxxxx, Cambridge, Massachusetts, USA 02138, Biochemie West Indies, N.V., a Netherlands Antilles corporation (“BCWI”) with a principal place of business at Xxxxxxxxxx 0X, Xxxxxxxxxx, Xxxxxxx, Xxxxxxxxxxx Antilles, and Geneva Pharmaceuticals, Inc., a Colorado corporation (“Sandoz”) with a principal place of business at 000 Xxxxxxxx Xxxxxx, Xxxxx 000, Xxxxxxxxx, Xxx Xxxxxx XXX 00000 (Sandoz, collectively with BCWI, are the “Sandoz Parties”, and individually, each is a “Sandoz Party”).
Collaboration and License Agreement. The Collaboration and License Agreement shall be in full force and effect, and the Effective Date (under and as defined therein) shall have occurred (or shall occur simultaneously with the Closing).
